Food News and Research

RSS

CCNI announces grant for daycare providers

Child Care & Nutrition, Inc. (CCNI) is pleased to announce a grant for daycare providers who apply for licensing for the first time in most areas of Minnesota.

5 Jan 2010

Cornell study shows we pour too little or too much medicine, depending on spoon size

A new study published in the Jan. 5 issue of the Annals of Internal Medicine illustrates the dangers of using kitchen spoons to measure liquid medicine.

5 Jan 2010

U.S. can reduce healthcare expenditures with cost-cutting tools

The United States could cut its per capita health care spending by double-digit percentages if it took full advantage of the cost-cutting tools now available, according to an article in the Winter 2010 Issues in Science and Technology.

5 Jan 2010

Majority of Medicaid patients on antipsychotic drugs do not undergo metabolic tests, says study

Despite government warnings and professional recommendations about diabetes risks associated with second-generation antipsychotic drugs, fewer than one-third of Medicaid patients who are treated with these medications undergo tests of blood glucose or lipid levels, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

5 Jan 2010

VELCADE sNDA receives FDA approval

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

5 Jan 2010

Book reveals new evidence of obesity-causing chemicals in American diet

The New American Diet, a groundbreaking new book by Men’s Health Editor-at-Large Stephen Perrine and Heather Hurlock, reveals the powerful new scientific evidence about obesity-causing chemicals lurking in the American diet – chemicals that disrupt our hormonal systems ultimately triggering substantial weight gain.

5 Jan 2010

Talampanel slows progression of amyotrophic lateral sclerosis

A drug already used to treat symptoms of epilepsy has potential to slow the muscle weakening that comes with amyotrophic lateral sclerosis (ALS), scientists report after completing a Phase II clinical trial-an early, small-scale test to show if the drug works and continues to be safe.

5 Jan 2010

New study reveals choline plays a critical role in fetal brain development

If you're pregnant and looking for an excuse to eat bacon and eggs, now you've got one: a new research study published in the January 2010 print issue of the FASEB Journal (http://www.fasebj.org) by a team of University of North Carolina researchers shows that choline plays a critical role in helping fetal brains develop regions associated with memory. Choline is found in meats, including pork, as well as chicken eggs.

5 Jan 2010

FDA approves generic donepezil hydrochloride orally disintegrating tablets

The U.S. Food and Drug Administration approved the first generic versions of Aricept (donepezil hydrochloride) orally disintegrating tablets on Dec. 11. Donepezil hydrochloride is indicated for the treatment of dementia related to Alzheimer's disease.

5 Jan 2010

Independent examines diseases that jump from animals to humans

The Independent examines the expansion of human diseases that originated in animals. "At least 45 diseases that have passed from animals to humans have been reported to U.N. agencies in the last two decades, with the number expected to escalate in the coming years," the Independent writes.

5 Jan 2010

Elusys Therapeutics signs contract to complete the final development of Anthim

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, announced today that it has signed a contract potentially totaling up to $143 million to complete the final development, commercial manufacturing and licensure of Anthim, the company's late stage anthrax therapeutic.

5 Jan 2010

NeoPharm submits IL13-PE38QQR IND for the treatment of IPF

NeoPharm, Inc., announced today that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is the most deadly disease of the lungs in humans with very high morbidity. There is currently no proven effective treatment for the cure of this disease.

5 Jan 2010

Boston Scientific commences enrollment in its TAXUS Liberte Stent System study

Boston Scientific Corporation today announced that it has enrolled the first patient in its TAXUS Liberte post-approval study. The study is designed to evaluate real-world clinical outcomes data for the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System in combination with a dual antiplatelet therapy drug regimen that includes aspirin and Effient®, a new antiplatelet medication. Co-sponsors of the study include Eli Lilly and Company and Daiichi Sankyo, Inc., manufacturers of Effient, which was recently approved by the U.S. Food and Drug Administration (FDA).

4 Jan 2010

DSPA submits lurasidone NDA to the FDA

Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia. The application, submitted on December 30, 2009, includes data from more than 40 clinical studies involving more than 2,500 lurasidone-treated patients.

4 Jan 2010

Cardiogenesis submits an IDE for its PHOENIX System

Cardiogenesis Corporation, today announced that it has submitted an IDE (Investigational Device Exemption) to the Food and Drug Administration to initiate a safety and feasibility trial for its PHOENIX System in patients with refractory angina. The PHOENIX handpiece is the first device specifically designed to allow physician-directed tissue stimulation and injections of biologic or pharmacologic agents to pre-determined areas of myocardium.

4 Jan 2010

FDA grants Priority Review designation for InterMune's NDA for pirfenidone

InterMune, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review designation for the company's New Drug Application (NDA) for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

4 Jan 2010